Fuhong Hanlin: The application for Phase I clinical trial of HLX3902 injection was approved by the National Medical Products Administration.

Fuhong Hanlin announcement: Recently, the company's self-developed HLX3902 injection for the treatment of metastatic castration-resistant prostate cancer and other advanced solid tumors has been approved for a Phase 1 clinical trial application by the National Medical Products Administration. HLX3902 is a company's self-developed three-specific monoclonal antibody drug intended for the treatment of metastatic castration-resistant prostate cancer and other advanced solid tumors.